
Neumora Therapeutics, Inc.: shareholders and insiders
Price
$0.33
November 20, 2026Market cap $61M
What Ploutos Investor adds for Neumora Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Aug 21, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$784.3K
4 people
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan1%
- The rest99%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $784.1K by 4 people
- 2025: no buys, no sales
- 2026: no buys, sold $784.1K by 4 people
- Aug 21, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 21, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 21, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 21, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 20, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 20, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 20, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 20, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 20, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 19, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 19, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 19, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 19, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 19, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 18, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 18, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 18, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 18, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 17, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 17, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 17, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 17, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 17, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 17, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
- Aug 17, 2026Daljit Singh AuroraChief Operating and Development OfficerKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 21, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 20.6K | $0.72 | $14.8K | Form 4 | |
| Aug 21, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 20.6K | $1.59 | $32.8K | Form 4 | |
| Aug 21, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 21.1K | $0.72 | $15.2K | Form 4 | |
| Aug 21, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 21.1K | $1.60 | $33.6K | Form 4 | |
| Aug 20, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 67.7K | $0.72 | $48.8K | Form 4 | |
| Aug 20, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 67.7K | $1.51 | $102.6K | Form 4 | |
| Aug 20, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 21.7K | $0.72 | $15.6K | Form 4 | |
| Aug 20, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 45.0K | $0.72 | $32.4K | Form 4 | |
| Aug 20, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 66.7K | $1.51 | $101.0K | Form 4 | |
| Aug 19, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 13.3K | $0.72 | $9.6K | Form 4 | |
| Aug 19, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 17.7K | $0.72 | $12.8K | Form 4 | |
| Aug 19, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 31.0K | $1.65 | $51.0K | Form 4 | |
| Aug 19, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 30.9K | $0.72 | $22.3K | Form 4 | |
| Aug 19, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 30.9K | $1.65 | $50.9K | Form 4 | |
| Aug 18, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 34.2K | $0.72 | $24.6K | Form 4 | |
| Aug 18, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 34.2K | $1.58 | $54.1K | Form 4 | |
| Aug 18, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 35.0K | $0.72 | $25.2K | Form 4 | |
| Aug 18, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 35.0K | $1.59 | $55.5K | Form 4 | |
| Aug 17, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 40.9K | $0.72 | $29.4K | Form 4 | |
| Aug 17, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 15.4K | $0.72 | $11.1K | Form 4 | |
| Aug 17, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 1,424 | $0.72 | $1.0K | Form 4 | |
| Aug 17, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 1 | $0.72 | $1 | Form 4 | |
| Aug 17, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 57.7K | $1.51 | $86.8K | Form 4 | |
| Aug 17, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 34.0K | $1.49 | $50.5K | Form 4 | |
| Aug 17, 2026 | Daljit Singh AuroraChief Operating and Development Officer | 25.3K | $0.72 | $18.2K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 29, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by NMRA's officers and directors from 2023 up to November 21, 2025, 3 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
Fell to 5% or less (3)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter+24%
- Millennium Mgmt (Englander)In the quarter-35%
- Renaissance TechnologiesIn the quarter-11%
- AQR CapitalIn the quarter×225
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 1.03M | +24% | $600.0K | 0.00% |
| Millennium Mgmt (Englander) | 328.5K | -35% | $200.0K | 0.00% |
| Renaissance Technologies | 1.13M | -11% | $700.0K | 0.00% |
| AQR Capital | 3.06M | ×225 | $1.8M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 3.10% of its shares outstanding were held short, -15.7% since the report before.
- Shares held short
- 5.64M
- 3.10%
- Since the report before6.69M on Sep 30, 2026
- -15.7%
- 2.3
- 2.43M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 27%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 2.41M
- Nov 15, 2023: Shares held short 2.52M
- Nov 30, 2023: Shares held short 2.77M
- Dec 15, 2023: Shares held short 3.23M
- Dec 29, 2023: Shares held short 3.29M
- Jan 12, 2024: Shares held short 3.58M
- Jan 31, 2024: Shares held short 4.50M
- Feb 15, 2024: Shares held short 5.00M
- Feb 29, 2024: Shares held short 4.90M
- Mar 15, 2024: Shares held short 5.03M
- Mar 28, 2024: Shares held short 4.92M
- Apr 15, 2024: Shares held short 5.87M
- Apr 30, 2024: Shares held short 6.58M
- May 15, 2024: Shares held short 6.31M
- May 31, 2024: Shares held short 6.58M
- Jun 14, 2024: Shares held short 6.42M
- Jun 28, 2024: Shares held short 7.30M
- Jul 15, 2024: Shares held short 8.86M
- Jul 31, 2024: Shares held short 9.15M
- Aug 15, 2024: Shares held short 9.60M
- Aug 30, 2024: Shares held short 9.98M
- Sep 13, 2024: Shares held short 9.52M
- Sep 30, 2024: Shares held short 9.68M
- Oct 15, 2024: Shares held short 9.01M
- Oct 31, 2024: Shares held short 9.37M
- Nov 15, 2024: Shares held short 9.81M
- Nov 29, 2024: Shares held short 10.46M
- Dec 13, 2024: Shares held short 10.83M
- Dec 31, 2024: Shares held short 12.99M
- Jan 15, 2025: Shares held short 11.03M
- Jan 31, 2025: Shares held short 10.26M
- Feb 14, 2025: Shares held short 11.20M
- Feb 28, 2025: Shares held short 12.28M
- Mar 14, 2025: Shares held short 12.89M
- Mar 31, 2025: Shares held short 12.83M
- Apr 15, 2025: Shares held short 13.30M
- Apr 30, 2025: Shares held short 12.78M
- May 15, 2025: Shares held short 13.66M
- May 30, 2025: Shares held short 15.02M
- Jun 13, 2025: Shares held short 14.54M
- Jun 30, 2025: Shares held short 10.52M
- Jul 15, 2025: Shares held short 9.03M
- Jul 31, 2025: Shares held short 7.16M
- Aug 15, 2025: Shares held short 5.28M
- Aug 29, 2025: Shares held short 5.23M
- Sep 15, 2025: Shares held short 6.42M
- Sep 30, 2025: Shares held short 6.78M
- Oct 15, 2025: Shares held short 6.79M
- Oct 31, 2025: Shares held short 6.54M
- Nov 14, 2025: Shares held short 6.10M
- Nov 28, 2025: Shares held short 6.47M
- Dec 15, 2025: Shares held short 6.98M
- Dec 31, 2025: Shares held short 7.50M
- Jan 15, 2026: Shares held short 5.99M
- Jan 30, 2026: Shares held short 5.63M
- Feb 13, 2026: Shares held short 6.05M
- Feb 27, 2026: Shares held short 5.22M
- Mar 13, 2026: Shares held short 4.96M
- Mar 31, 2026: Shares held short 4.33M
- Apr 15, 2026: Shares held short 4.47M
- Apr 30, 2026: Shares held short 4.60M
- May 15, 2026: Shares held short 4.90M
- May 29, 2026: Shares held short 5.58M
- Jun 15, 2026: Shares held short 4.92M
- Jun 30, 2026: Shares held short 6.68M
- Jul 15, 2026: Shares held short 7.79M
- Jul 31, 2026: Shares held short 7.62M
- Aug 14, 2026: Shares held short 7.99M
- Aug 31, 2026: Shares held short 8.03M
- Sep 15, 2026: Shares held short 6.98M
- Sep 30, 2026: Shares held short 6.69M
- Oct 15, 2026: Shares held short 5.64M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading57.3% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 57.3% of the shares in the reported trades were short sales, against 61.5% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 57.3%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 61.5%
- Change
- -4.2 pts
- Short sales a dayon average, of 762.4K shares
- 437.2K
- More than atof 3,666 US-listed companies, same days
- 75%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 76.7%
- Oct 15, 2026: Short sales 66.9%
- Oct 16, 2026: Short sales 57.5%
- Oct 19, 2026: Short sales 59.7%
- Oct 20, 2026: Short sales 62.9%
- Oct 21, 2026: Short sales 40.7%
- Oct 22, 2026: Short sales 68.9%
- Oct 23, 2026: Short sales 71.3%
- Oct 26, 2026: Short sales 74%
- Oct 27, 2026: Short sales 59.8%
- Oct 28, 2026: Short sales 59.2%
- Oct 29, 2026: Short sales 37.4%
- Oct 30, 2026: Short sales 64%
- Nov 2, 2026: Short sales 57.7%
- Nov 3, 2026: Short sales 53.8%
- Nov 4, 2026: Short sales 44.5%
- Nov 5, 2026: Short sales 59.7%
- Nov 6, 2026: Short sales 66.6%
- Nov 9, 2026: Short sales 48.7%
- Nov 10, 2026: Short sales 37.8%
- Nov 11, 2026: Short sales 49.4%
- Nov 12, 2026: Short sales 66.6%
- Nov 13, 2026: Short sales 55.1%
- Nov 16, 2026: Short sales 56.8%
- Nov 17, 2026: Short sales 77.6%
- Nov 18, 2026: Short sales 62.6%
- Nov 19, 2026: Short sales 67%
- Nov 20, 2026: Short sales 73.4%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Paul L BernsSee RemarksDirectly7.40M
- ARCH Venture Partners VIII, LLCTenPercentOwnerDirectly–
- ARCH Venture Partners XII, LLCTenPercentOwnerDirectly–
- Kristina BurowDirector,TenPercentOwnerDirectly–
- Robert A. LenzHead of R&DDirectly309.1K
- Joshua PintoPresidentDirectly57.8K
- Daljit Singh AuroraSee RemarksDirectly48.8K
- Michael Lee MilliganSee RemarksDirectly21.0K
- Matthew K FustDirectorDirectly20.1K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Paul L BernsSee Remarks | 7.40M | – | Feb 17, 2026 | Form 4 |
| ARCH Venture Partners VIII, LLCTenPercentOwner | – | 6.05M | Oct 27, 2025 | Form 4 |
| ARCH Venture Partners XII, LLCTenPercentOwner | – | 6.05M | Oct 27, 2025 | Form 4 |
| Kristina BurowDirector,TenPercentOwner | – | 6.05M | Oct 27, 2025 | Form 4 |
| Robert A. LenzHead of R&D | 309.1K | – | Feb 18, 2025 | Form 4 |
| Joshua PintoPresident | 57.8K | 139.0K | Feb 17, 2026 | Form 4 |
| Daljit Singh AuroraSee Remarks | 48.8K | – | Aug 21, 2026 | Form 4 |
| Michael Lee MilliganSee Remarks | 21.0K | – | Feb 17, 2026 | Form 4 |
| Matthew K FustDirector | 20.1K | – | Oct 18, 2024 | Form 4 |
A lower bound: it counts only the 9 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.04%
- IBBiShares Biotechnology ETFWeight in the fund0.01%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.01%
- IWMiShares Russell 2000 ETFWeight in the fund0.01%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.00%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.00%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.00%
- VXFVanguard Extended Market Index FundWeight in the fund0.00%
- VHTVanguard Health Care Index FundWeight in the fund0.00%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
11 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 93
- Q4 2025: Managers 102
- Q1 2026: Managers 115
- Q2 2026: Managers 113
Institutional investors by quarter
The fund managers holding NMRA, quarter by quarter, from Q3 2023 to Q2 2025, 8 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 113 managers held 75.99M shares, worth $129M. During the quarter 28 opened a position, 30 closed one, 34 added and 23 trimmed.
The largest holders, Q2 2026
- SirenIn the quarter
- BlackRockIn the quarter+279%
- Softbank GroupIn the quarter
- Vanguard Capital ManagementIn the quarter+20%
- MIC Capital Management UKIn the quarter
- FMRIn the quarter
- WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUSTIn the quarter
- Geode Capital ManagementIn the quarter+140%
- ICONIQ CapitalIn the quarter
- Two Sigma InvestmentsIn the quarter+10%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Siren | 8.50M | $14M | |
| BlackRock | 7.79M | +279% | $13M |
| Softbank Group | 6.09M | $10M | |
| Vanguard Capital Management | 4.67M | +20% | $7.9M |
| MIC Capital Management UK | 4.46M | $7.6M | |
| FMR | 3.50M | $5.9M | |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | 3.31M | $5.6M | |
| Geode Capital Management | 2.61M | +140% | $4.4M |
| ICONIQ Capital | 2.56M | $4.4M | |
| Two Sigma Investments | 2.24M | +10% | $3.8M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Neumora Therapeutics's filings show?
Who buys and sells is one part of Neumora Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have NMRA's insiders bought or sold?
From May 29, 2026 to Aug 21, 2026 Neumora Therapeutics's insiders bought 0 and sold $701.6K of shares on the market. 0% of the sales were under set 10b5-1 plans.
Which well-known managers hold NMRA?
4 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $1.8M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.